Latest Developments and New Research in ADC Technologies Presented by Catalent and Redwood Biosciences at BIO International Convention
Somerset, N.J. – June 19, 2014 – Senior Executives from Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, are to present at the forthcoming BIO International conference, which takes place from June 23rd to 26th at the San Diego Convention Center, San Diego, CA.
Dr. Greg Bleck, R&D Platform Director-Biologics is to present, “Site Specific ADC Generation Using SMARTag™ Technology,” on Tuesday, June 24th at 10.00 a.m., and he will discuss ways in which Antibody Drug Conjugates (ADCs) can be engineered with proprietary aldehyde-tagging technology and novel conjugation and linker chemistries to enhance efficacy, safety and stability. His presentation will include new in vivo data showing that ADCs generated using the SMARTag system compared favorably to conventionally engineered ADCs. This work supports the importance of payload conjugation site, linker design and the conjugation chemistry provided by the SMARTag platform. Catalent has an exclusive license to market the proprietary SMARTag technology from Redwood Bioscience.
On the same day, at 12.00 p.m., Dr. David Rabuka, Founder, President and Chief Scientific Officer of Redwood Bioscience Inc., will participate in a round table discussion “The History, Challenges, and Promise of Antibody Drug Conjugates”.
Additionally, Mr. Andrew Sandford, Catalent’s Vice President, Biologics will be participating in a round table discussion entitled, “CMO/CDMO: How Technologies are Changing Outsourcing Strategies, Services Offered, and Risks Taken,” where he will discuss Catalent’s advancements and competitive advantages in the area of biologics. The round table discussion will take place on Thursday, June 26th
at 12:00 p.m.
Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in Molecular Biology and Transgenic animals with 12 years’ experience within the organization. Dr. Bleck holds a Bachelor’s degree in Dairy Science and a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Dr. Bleck has published more than 55 research papers and co-authored chapters in three books.
Dr. Rabuka received a Ph.D. in Chemistry at the University of California, Berkeley, as a Chevron Fellow in the lab of Professor Carolyn Bertozzi. His research included developing and applying Redwood’s platform technology to cell surface modifications. Prior to joining Professor Bertozzi’s lab, Dr. Rabuka worked at the Burnham Institute, synthesizing complex glycans, followed by Optimer Pharmaceuticals, where he was an early employee, focused on the development of glycan and macrolide based antibiotics. He graduated with a double honors B.S. in Chemistry and Biochemistry from the University of Saskatchewan where he received the Dean’s Science Award and holds a M.S. in Chemistry from the University of Alberta. Dr. Rabuka is an author on over 20 major publications, as well as numerous book chapters and patents.
Mr. Sandford joined Catalent earlier this year from Selexis, Inc., a subsidiary of Selexis SA, where he established the U.S. subsidiary of the company and was responsible for global transactional and strategic value creation. Prior to this, he worked with Dow Chemical’s Ventures Business Unit; Dowpharma, and Cambrex Biopharma, which was latterly acquired by Lonza Biologics. A microbiologist by education, Mr. Sandford holds a BS from the State University of New York at Plattsburgh
Catalent’s proprietary GPEx®
cell line expression system, its new state-of-the-art biomanufacturing Center of Excellence in Madison, Wisconsin, SMARTag ADC technology, and broad range of analytical and fill-finish services, combine to make a broad range of biologic technologies to help customers develop more and better biologic treatments.
ABOUT CATALENT
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2013 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com